Catalent Inc (NASDAQ:CTLT) – Jefferies Group increased their Q1 2017 EPS estimates for shares of Catalent in a report released on Thursday. Jefferies Group analyst D. Windley now forecasts that the brokerage will post earnings per share of $0.13 for the quarter, up from their previous forecast of $0.12. Jefferies Group has a “Hold” rating and a $28.00 price objective on the stock. Jefferies Group also issued estimates for Catalent’s Q2 2017 earnings at $0.30 EPS and Q3 2017 earnings at $0.33 EPS.
A number of other equities research analysts also recently weighed in on CTLT. Morgan Stanley reiterated a “hold” rating on shares of Catalent in a report on Tuesday, August 30th. Wells Fargo & Co. upgraded Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. Zacks Investment Research upgraded Catalent from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 5th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $30.00 target price (down from $30.50) on shares of Catalent in a report on Tuesday, August 30th. Finally, TheStreet upgraded Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. Catalent presently has a consensus rating of “Hold” and a consensus price target of $28.67.
Shares of Catalent (NASDAQ:CTLT) opened at 25.84 on Friday. The firm has a market cap of $3.22 billion and a P/E ratio of 29.03. The stock has a 50 day moving average of $25.22 and a 200 day moving average of $25.66. Catalent has a 52 week low of $18.92 and a 52 week high of $32.24.
Catalent (NASDAQ:CTLT) last announced its quarterly earnings data on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by $0.01. The firm had revenue of $532.20 million for the quarter. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.61 EPS.
A number of large investors have recently made changes to their positions in CTLT. Pacer Advisors Inc. purchased a new stake in shares of Catalent during the second quarter worth approximately $102,000. Barclays PLC boosted its position in shares of Catalent by 406.7% in the second quarter. Barclays PLC now owns 5,275 shares of the company’s stock valued at $121,000 after buying an additional 4,234 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in shares of Catalent during the second quarter valued at about $123,000. LS Investment Advisors LLC boosted its position in shares of Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock valued at $164,000 after buying an additional 3,280 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in shares of Catalent during the second quarter valued at about $196,000.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the firm’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $23.58, for a total value of $403,234,623.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.